Venetoclax Active in Heavily Treated Multiple Myeloma

Published: Wednesday, Dec 21, 2016

Shaji Kumar, MD

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma, according to results of a phase I clinical trial presented at the 2016 ASH Annual Meeting.¹

References

Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Presented at: 58th ASH Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA. Abstract 488.
Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210-212.
Punnoose EA, Leverson JD, Peale F. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132-1144.

... to read the full story

To Read the Full Story

View Other News on Multiple Myeloma

View Conference Coverage

2019 ASCO Annual Meeting

2019 State of the Science Summit on Genitourinary Cancers in Needham

2019 State of the Science Summit on Hematologic Malignancies in Wisconsin

2019 European Lung Cancer Congress

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma	May 30, 2019	2.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer Conference	May 30, 2019	6.5